Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): Influence of CYP2D6 expression and other factors

Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2009, Pages 17-29

  Mao, Zhongping L ^a   Wheeler, Jeffery J ^b   Clohs, Lilian ^b   Beatch, Gregory N ^b   Keirns, James ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b Cardiome Pharma Corp   (Canada)

Author keywords

Atrial fibrillation; CYP2D6 genotype; Pharmacokinetics; RSD1235; Vernakalant

Indexed keywords

CYTOCHROME P450 2D6; PLACEBO; VERNAKALANT;

ACUTE DRUG ADMINISTRATION; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; PHARMACOGENOMICS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART ATRIA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRROLIDINES; SEX FACTORS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 58149194828     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008325148     Document Type: Article

References (22)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001 ; 285: 2370-2375.
2. Ayala C., Wattingney WA, Croft JB, et al. Public health and aging: atrial fibrillation as a contributing cause of death and Medicare hospitalization- United States, 1999. MMWR Morb Mortal Wkly. 2003 ; 52: 128-131.
3. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 ; 22: 983-988.
4. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 ; 98: 946-952.
5. Roy D., Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004 ; 44: 2355-2361.
6. Nichol G., McAlister F., Pham B., et al. Meta-analysis of randomized controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002 ; 87: 535-543.
7. Fedida D., Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005 ; 16: 1227-1238.
8. Beatch GN, Lin S., Hesketh JC, Johnson BD, Ezrin AM, Fedida D. Electrophysiological mechanism of RSD 1235, a new atrial fibrillation converting drug. Circulation. 2003 ; 108 (suppl IV). 85.
9. Beatch GN, Shinagawa K., Johnson B., et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Pacing Clin Electrophysiol. 2002 ; 25: 698.
10. Dorian P., Pinter A., Mangat I., et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007 ; 50 (1). 35-40.
11. Roy D., Pratt CM, Torp-Pedersen C.,, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 ; 117: 1518-1525.
12. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects, and functional diversity. Pharmacogenomics J. 2005 ; 5 (1). 6-13.
13. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest. 2003 ; 33 (suppl 2). 17-22.
14. Daly AK Pharmacogenetics of the cytochrome P450. Curr Topics Med Chem. 2004 ; 4: 1733-1744.
15. Paine AJ Heterogeneity of cytochrome P450 and its toxicological significance. Human Exper Toxicol. 1995 ; 14: 1-7.
16. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995 ; 29: 192-209.
17. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003 ; 23: 31-35.
18. Bradford LD, Kirlin WG Polymorphism of CYP2D6 in black populations: implications for psychopharmacology. Int J Neuropsychopharmacol. 1998 ; 1: 173-185.
19. Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med. 1997 ; 157 (10). 1070-1076.
20. Ezrin AM, Grant SM, Bell G., et al. A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers. Pharmacologist. 2002 ; 44 (2, Supplement 1). A15.
21. Schmid B., Bircher J., Preisig R., Kuepfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther. 1985 ; 38: 614-624.
22. Kroemer HK, Klotz U. Glucuronidation of drugs. A reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet. 1992 ; 23: 292-310.